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Patient Reported Efficacy of Botulinum Toxin Type A in the Treatment of Chronic
Migraine Headaches
Patrick F. Whitney
ABSTRACT
Objective: To assess patient reported efficacy of Botulinum toxin type-A for the
prophylaxis of migraine headaches in patients with frequent migraine headaches prior to
initiation of treatment with Botulinum toxin type-A compared to post treatment.
Questions addressed include is there a difference in frequency of migraine headaches
following treatment with Botulinum toxin type-A, is there a difference in cost of
conventional treatment versus Botulinum toxin type-A and is there a difference in quality
of life.
Research Plan: Questions addressed patient status prior to the initiation of treatment as
well as post treatment. Patient quality of life change, duration and frequency headache
improvement are the primary focus. Other considerations included the cost difference
between the previous use of other treatment and the periodic treatment with Botulinum
toxin type-A.
Methodology: A Cross Sectional study utilizing a questionnaire consisting of a modified
Migraine Disability Assessment (MIDAS) questionnaire will be given to patients who
had received more than one series of injections. Patients who reported chronic migraine
headaches and were refractory to previous treatment methods were screened and placed
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in programs utilizing intramuscular injection of Botulinum toxin type-A at standard
points on the face, Temporalis muscle and paracervical muscles.
Clinical Relevance:

This assessment is relevant to occupational issues due to the

increasing number of patients applying for disability due to uncontrolled migraine
headaches as well as lost productivity and reduction in functional capacity for activities
of daily living.
Impact and Significance: Patient’s that are debilitated by recurrent chronic migraine
headaches suffer loss of productive time at work and home. Treatment with Botulinum
toxin type-A may results in significant relief allowing fewer days lost at work and
improved quality of life. There may be significant cost saving if treatment results in
discontinuation of other medications previously used for treatment of migraine
headaches.
Findings: According to the patients’ responses to this survey, it appears that there was
an overall improvement in the patients’ ability to do work, for those who were employed,
as well as their ability to do activities of daily living post treatment with Botulinum toxinA. Though there were occasionally conflicting data seen in individual cases regarding
responses to some of the answers, there appeared to be an overall statistically significant
reduction in the mean of responses to the questions. The general implication is consistent
with studies that indicate Botulinum toxin-A may be a useful adjunct in the prophylactic
treatment of refractory migraine headaches.

v

Background
Migraine headaches have become a significant source of lost work in the US. Social
Security disability claims arising from migraine headaches have become more
increasingly more common in recent years. It is estimated that 30 million Americans
suffer occasionally or regularly with migraine headaches. It is estimated that 113 million
lost work days are due to migraines with $13 billion of lost productivity

(1).

Migraine

ranks in the top 20 of the world's most disabling medical illnesses. Estimates of the US
population suffering from migraine headaches vary in range from 2 - 10% (1,2). The onset
of a migraine headache is potentially disabling in itself, however many sufferers live
knowing that at any time the onset of a headache could disrupt their ability to work, go to
school, care for their families or generally interfere with activities of daily living. Less
than 10% of those with migraine history are able to work or function normally during
their migraine attacks (1). About 12 million people experience these attacks on an almost
daily basis placing them well outside of the average rate of once or twice a month for the
typical migraine headache sufferer. These may be referred to as chronic daily headache
(CDH) and are defined as a group of disorders characterized by very frequent headaches
occurring 15 days a month and include those headaches associated with medication
overuse

(3).

In the US, women have a higher prevalence than men at an estimated 18%

vs. 6%. Over 30 million people in the United States cause American employers lose
more than $13 billion each year as a result of 113 million lost work days due to migraine
headaches. In the 2005 European Journal of Neurology, it was estimated that migraine
1

headaches were the most costly neurological disorder in the European Community
costing more than €27 billion per year (15). Annual employer cost of lost productivity due
to migraines has been estimated at $3,309 per sufferer. Total medical costs associated
with migraines in the United States amounted to one billion dollars in 1994 and when
combined with the cost of lost productivity is estimated at thirteen to seventeen billion
dollars per year.

In a recent aritcle published in the Journal of Occupational and

Environmental Medicine, a study was published evaluating the impact on the workplace
of chronic migraine headaches as compared to episodic migraine headaches

(65).

Estimates of lost productivity time were based on 2005 data derived from American
Migriane Prevalence and Prevention (AMPP) study. This was a large study surveying
11,000 individuals with migraine headaches. The survey was done on patients over 18
years of age suffering from at least occasional self defined severe headaches. Migraine
case definition included established critreia of unilateral or pulsatile pain with nausea,
vomiting, phonophobia, photophobia or unusual aura preceeding the headache. The
questionairre was initiated in 2004 with a second follow up survey in 2005. The results
of the study indicate that individuals with chronic migraine headaches were 19% less
likely to be working as compared to those who experienced headaches at less than or
equal to 3 headace days per month. The average time lost per week for those with
chronic migraine headaches was 4.6 hours as compared to only 1.1 hours per week for
those with less frequent headaches. Those in the chronic migraine group accounted for
20.8% of lost productivity time and 35% of overall lost work time when factoring in
medical leave and unemployment. The study concluded that the impact of chronic

2

migraine headaches as well as episodic migraine headaches would be underestimated if
employment status is not measured (65).
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Migraine Mechanism
Migraine attacks often include features that occur in sequence beginning with the
prodrome stage. This stage is marked by a change in mood that begins hours or days
before the headache. Symptoms of prodrome include depression, sleepiness,
talkativeness, restlessness, or other alterations

(6).

Next is the Aura phase characterized

by visual abnormalities, including flashes, shimmering, and other hallucinations. Finally
the headache phase occurs. The headache itself is typically one sided but may also
present as bilateral. It is usually gradual in onset with moderate to severe in pain
intensity. Throbbing and worse pain occurs with physical exertion. The headache can
last anywhere from 2 hours to 2 days in children and 4 hours to 3 days in adults

(6).

The

frequency of migraine attacks is difficult to predict. The headache stage is often
accompanied by decreased appetite, nausea, vomiting, sensitivity to light and sound,
blurred vision, tenderness of the scalp or neck, lightheadedness, sweating, and pallor

(6).

The cause of migraine headaches appears to be multifaceted consequently no single
treatment protocol has been uniformly successful leaving migraine patients dissatisfied
with treatment results. Numerous theories as to the origin and mechanism of migraine
headaches have been proposed over the years. One of the first theories to explain
migraines was the classic theory of vasoconstriction/vasodilatation. According to this
theory, migraine headaches are caused by the constriction of blood vessels in the brain
which is followed by vasodilatation

(7).

During the 1940s and 1950s, the vascular theory

was proposed to explain the pathophysiology of migraine headache. Wolff et al believed
4

that intracranial vasoconstriction is responsible for the aura of migraine and that the
subsequent rebound vasodilatation with activation of perivascular nociceptive nerves
resulted in headache. This theory was based on the observations that extracranial vessels
become distended and pulsatile during a migraine attack and stimulation of intracranial
vessels in an awake person induces headache. He also noted that vasoconstrictors such as
ergotamine improve the headache, whereas vasodilators such as nitroglycerin provoke an
attack. However, this theory has been challenged recently for several reasons. Brain
studies during migraine have shown that blood flow to the brain is in fact abnormal,
which likely contributes to the symptoms. The current view is that a complex series of
neural and vascular events initiates migraine. This view is now called the neurovascular
theory (11). Key features of the neurovascular theory include the following. At baseline, a
migraineur who is not having any headache has a state of neuronal hyperexcitability in
the cerebral cortex, especially in the occipital cortex

(12).

This finding has been

demonstrated in studies of transcranial magnetic stimulation and with functional MRI.
This observation explains the special susceptibility of the migrainous brain to headaches
(13).

There is speculation that there is a parallel with the patient with epilepsy who

similarly has interictal neuronal irritability. The theory of hyperexcitability expands on
the

theory

of

vasoconstriction/vasodilatation.

According

to

the

theory

of

hyperexcitability, the brains of migraine sufferers are more sensitive to normal triggers,
such as stress. The frequency of migraines depends on the level of excitability. An
external trigger may stimulate sudden constriction of the blood vessels in the brain
resulting in the onset of a migraine headache. It is theorized that the cause of this
excitability is due to abnormal brain chemistry, specifically in the relationship between
5

calcium and magnesium. Calcium flows from the extracellular fluid to the intracellular
space during periods of nerve excitability resulting in vasoconstriction. In theory
anything that blocks the flow of calcium or restores the balance of magnesium to calcium
would be helpful in mitigating migraine. Some studies have shown that calcium channel
blockers can successfully prevent migraine attacks due to blocking the flow of calcium
into cells

(8).

Another theory proposes that there is a derangement of serotonin

metabolism and an excess of neurotransmitters. During migraine, serotonin levels are
depressed in the brain. Triptans selectively stimulate certain serotonin receptors and have
been shown to reduce the symptoms of migraine

(9).

This theory is supported by the fact

that melatonin, secreted by the pineal gland along with serotonin, is also reduced during
migraine. This suggests that the pineal gland is depressed in migraine patients (10). High
levels of steroid hormones, primarily estrogen, can interact with the serotonin transport
system. This further compromises the availability of serotonin. Other parts of the nervous
system are also implicated in migraines. The sympathetic nervous system is responsible
for many functions including increasing the contractility of smooth muscle and increasing
the heart rate. Many of the reported factors that trigger migraine, such as stress and
hormonal changes, also act on the sympathetic nervous system
mimic or enhance norepinephrine may alleviate migraine

(9).

(9).

Similarly, drugs that

Some evidence implicates

steroid hormonal imbalances in migraine. Reports by women note that their migraine
attacks occur in connection with their menses. Abnormal hormone levels have been
suspected as closely associated with migraine headaches.

As previously discussed,

occasionally a small percentage of migraine sufferers will fall into the category of
chronic daily headaches. Current diagnostic criteria used to define CDH were published
6

by the International Headache Society in 2004. According to these criteria, primary
chronic daily headache (CDH) is defined as daily or almost daily migrainous headache
that occurs for more than 15 days a month, for greater than 3 months, and has no
structural or infectious causes. Associated symptoms of nausea, vomiting, photophobia,
and phonophobia may be less frequent in chronic migraineur. The pathogenesis of
chronic daily headache is not well understood, and some believe that it is due to a central
mechanism involving an alteration in serotonergic and monoaminergic pathways to the
brainstem and hypothalamus

(14).

Chronic daily headaches have been associated with an

increased frequency of primarily psychiatric comorbid conditions such as depression,
anxiety, bipolar disorders, panic attacks, oromandibular dysfunction, stress, and drug
overuse.
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Management
Acute treatment of migraine headaches involves the use of medications intended to
relieve the symptoms of attacks when they occur. Migraine headache preventative efforts
involve the use medications taken daily to reduce the number of attacks and lessen the
intensity of pain. Some patients may respond to alternative treatment such as lifestyle
changes, relaxation techniques, acupuncture, exercise, proper rest and dietary
modification. Typically these are referred to as complementary treatment and may help
avoid the triggering of attacks.

Medication overuse, commonly known as rebound

headache, can have a significant influence on initiation of migraine headaches

(4).

Standard medical approach to managing migraine headaches include preventative or
prophylactic measures, trigger management, abortive measures and pain management of
the headache once it occurs. Typically preventative measures have relied on the use of
medications that were never intended to treat headaches. These include beta blockers,
calcium channel blockers, Methylsergide or Divalproex Sodium.

Beta-blockers,

primarily Propranolol, are one of the most commonly prescribed prophylactic treatments
for Migraine and are considered to be an effective preventive treatment.

Calcium

channel blockers are thought to play a role in migraine prevention by affecting blood
vessel constriction as previously discussed.

Methysergide is thought to block the

inflammatory and vessel-constricting effects of serotonin. Because of potential sideeffects, Methysergide is generally used only on select patients. Some of the known
potential side effects include retroperitoneal fibrosis which may be severe but
8

uncommon. Other severe but uncommon side effects include pleural fibrosis and
subendocardial fibrosis as well as an increased risk of left-sided cardiac valve
dysfunction

(5).

Because of the potential severity of these side effects, Methysergide

requires a four to six week drug hiatus every six months. Divalproex Sodium was
originally developed for Epilepsy. It is typically prescribed in smaller doses to treat
migraine headaches to reduce the potential side effects.

Management of migraine

triggers are effective if the trigger is known and can reasonably be avoided. Triggers are
different from person to person. Some examples of reported triggers include changes in
weather or air-pressure, bright sunlight, glare, fluorescent lights, chemical fumes,
menstrual cycles, and certain foods such as processed meats, red wine, beer, dried fish,
broad beans, fermented cheeses, aspartame, and MSG. Once the prodromal phase of the
migraine occurs and the headache is imminent, abortive measures may be initiated.
Abortive medications are used to relieve the severity, duration and associated symptoms
of the migraine headache. They are recommended to taken as early as possible in an
attack.

Cerebral vasoconstrictor abortive agents were formulated specifically for

migraine headaches. They may be administered by subcutaneous, oral, rectal, or
intramuscular means. Some of the common medications include ergotamine tartrate or
Dihydroergotamine, Sumatriptan, Naratriptan, Rizatriptan, Zolmitripan, Electriptan,
Frovatriptan and Isometheptene mucate. The nonvasoconstrictive abortive agent
Butorphanol tartrate may be administered by injection or nasal spray. Emergency
departments commonly use narcotic injections in combination with Promenthazine or
Hydroxyzine for nausea. These can offer an option if other measures fail or are not
appropriate for comorbid conditions such as heart disease or other medical condition that
9

would contraindicate their use. Once the headache starts, pain management may include
narcotic analgesics. These act on the nervous system receptors and alter the patient's
perception of pain. These drugs may relieve pain, however they may be addictive and
such usage should be done in an appropriate manner. Common narcotic medications
include

Butalbital with Codeine, Codeine, Acetaminophen and Oxycodone

hydrochloride, Meperidine hydrochloride, acetaminophen and codeine, Hydrocodone
bitartrate and acetaminophen or methadone. Though normally ineffective for relief of
migraine headaches, NSAIDs (non-steroidal anti-inflammatory drugs) act by inhibiting
blood vessel inflammation. These medications include Naproxen, Ibuprofen and
Ketorolac. Most are readily available over the counter in non prescription doses which
makes them accessible to the general public. Many migraine headache sufferers take
these OTC medications in inappropriate doses in a desperate attempt to relieve a
debilitating painful condition. Some migraineurs attempt to manage mild to moderate
attacks at home by using a variety of techniques which include using a cold compress to
the area of pain, resting with pillows comfortably supporting the head or neck in a room
with little or no sensory stimulation (light, sound, odors), avoiding stressful surroundings,
sleeping or consuming a moderate amount of caffeine. Other alternative treatments
include but are not limited to acupuncture, biofeedback, manipulation, massage and
nutritional (herbs, vitamins, minerals). Lifestyle and home remedies, as described by the
Mayo Clinic staff on their web page regarding migraines, mayoclinic.com, can include
muscle relaxation exercises, proper rest and keeping a headache diary to help learn more
about what triggers the migraines and what treatment is most effective. They also
indicate that Botulinum toxin type A is sometimes used for treatment of chronic
10

migraines. They state that studies have had mixed results with respect to effectiveness but
that some headache specialists believe that it can be helpful for some people. Injections
are made in muscles of the forehead and neck. When this is effective, the treatment
typically needs to be repeated every three months.
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Botulinum Neurotoxin Overview

Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium
botulinum, and is held to be the most toxic substance known to mankind

(16)

with an

LD50 of roughly 0.005–0.05 µg/kg. The flaccid muscular paralysis can be fatal in cases
of botulism. Ironically, this property is intentionally used as an advantage in medical
treatments.

The toxins are injected into the muscles at different sites on the body

resulting in temporary paralysis with effects lasting from 3 to 9 months. The toxin is a
microbial product synthesized by the anaerobic, gram-positive, spore forming bacteria
ubiquitously found in the soil. Historically Botulinum toxin has been considered a
byproduct of the bacteria resulting in spoiled food. The Botulinum toxin's most
significant adverse health effect is its prevention of neurotransmission causing paralysis.
Death occurs from Botulism primarily as a result of paralysis of the respiratory muscles
leading to respiratory failure

(19).

German physician Justinus Kerner (1786-1862) first

developed the idea of a possible therapeutic use of Botulinum toxin which he called
"sausage poison”. In 1928, Dr. Herman Sommer, at the University of California, San
Francisco, first isolated in purified form Botulinum toxin type A (BoNT-A) as a stable
acid precipitate. In the 1950s, Dr. Vernon Brooks discovered that when BoNT-A is
injected into a hyperactive muscle, it blocks the release of acetylcholine from motor
nerve endings. Work with Botulinum toxin type A as a therapeutic agent to treat human
disease began in the late 1960s through the collaboration of Alan B. Scott, MD, of the
Smith-Kettlewell Eye Research Foundation and Edward J. Schantz, PhD, director of food
12

microbiology and toxicology at the University of Wisconsin. This is when Botulinum
toxin type A was first considered as a powerful therapeutic agent to treat symptoms of
neurological disorders rather than an agent of human sickness and disease. In 1980, Dr.
Alan B. Scott, of Smith-Kettlewell Eye Research Institute, used Botulinum neurotoxin-A
for the first time in humans to treat strabismus. In December 1989, BTX-A (BOTOX)
was approved by the FDA for the treatment of strabismus, blepharospasm, and hemifacial
spasm in patients over 12 years old. Although the effect had been observed by a number
of independent groups, the cosmetic effect of BoNT-A was initially described by
ophthalmologist Jean Carruthers and dermatologist Alastair Carruthers working in
Vancouver, Canada. The FDA announced the approval of BOTOX® Cosmetic on April
15, 2002 as a treatment to temporarily improve the appearance of moderate to severe
frown lines between the eyebrows referred to as glabellar lines. BoNT is broken into 7
neurotoxins labeled types A, B, C [C1, C2], D, E, F, and G. They are all antigenically
and serologically distinct but structurally similar. Human botulism is primarily caused by
types A, B, E, and F. Types C and D are only toxic in animals. The toxin is a zinc
dependent protease that cleaves one or more of the fusion proteins by which neuronal
vesicles release acetylcholine (Ach) into the neuromuscular junction. It acts preferentially
on peripheral cholinergic nerve endings to block Ach release

(18).

The details of BoNT

mechanism are described by Takamizawa K, Iwamori M and Kozaki S, et al. The BoNT
molecule is synthesized as a single chain and then cleaved to form the dichain molecule
with a disulfide bridge. The light chain acts as a zinc endopeptidase similar to tetanus
toxin with proteolytic activity located at the N-terminal end. The heavy chain provides
cholinergic specificity and is responsible for binding the toxin to presynaptic receptors. It
13

also promotes light chain translocation across the endosomal membrane. Botulinum toxin
acts by binding presynaptically to high affinity recognition sites on the cholinergic nerve
terminals. This results in decreased the release of acetylcholine causing a neuromuscular
blocking effect. Specifically, Botulinum toxin cleaves SNARE proteins which are
involved with fusing synaptic vesicles to the plasma membrane. Cleaving of SNARE
proteins inhibits the release of acetylcholine at the neuromuscular junction leading to
inhibition of neurotransmission. Cleaving SNARE proteins creates a nonfunctional
SNARE complex disrupting calcium influx and fusion is disrupted.

Increasing the

calcium concentration in the synaptic terminal may diminish the effects of Botulinum
toxin. According to de Paiva A, Meunier FA, Molgó J, et al, recovery occurs through
proximal axonal sprouting and muscle reinnervation by formation of a new
neuromuscular junction. BoNT-A and BoNT-E cleave synaptosome associated protein
(SNAP-25), a presynaptic membrane protein required for fusion of neurotransmittercontaining vesicles

(17).

When BoNT-A is injected into a striate muscle, paresis occurs

after two to five days and lasts from two to three months before it gradually starts to wear
off. When Botulinum Toxin is injected into a target tissue it is almost completely bound
to the axon terminal

(20).

However, when BoNT-A is applied to treat cervical dystonia,

small fractions of the applied Botulinum toxin are distributed systemically and can be
detected by increase of neuromuscular jitter in non injected muscles (21). When Botulinum
Toxin-B is applied to treat cervical dystonia substantial systemic anticholinergic side
effects can be clinically detected

(18).

Despite its systemic distribution, direct Botulinum

Toxin effects on the CNS have not been reported. This is because Botulinum neurotoxin
with its size of 150 KiloDalton does not penetrate the blood brain barrier. Apart from
14

systemic penetration Botulinum toxin could theoretically reach the CNS by retrograde
axonal transport. Such retrograde axonal transport has been detected for Botulinum toxin
with radioactively labeled Botulinum neurotoxin

(22).

The Botulinum toxin was likely

inactivated before it reached the CNS since the retrograde axonal transport was so slow.
Transsynaptic transport was not observed. Botulinum Toxin action upon Renshaw cells
was only demonstrated after intraspinal injection (23). Effects of Botulinum Toxin on the
neuromuscular synapse and on the muscle spindle organs can produce various indirect
effects on the CNS. On the spinal level Botulinum Toxin produces reflex inhibition of
alpha motoneurons by gamma motoneuron blockade and subsequent Ia/II afferent input
suppression1(24,25). Botulinum toxin may normalize altered reciprocal inhibition between
flexor and extensor muscles in patients with upper limb dystonia
was also demonstrated in patients with essential tremor

(27).

(26).

A similar effect

EMG changes of the

contralateral ocular muscles after injection of Botulinum toxin into the lateral rectus
muscle also suggest central effects

(28).

Botulinum toxin may also normalize altered

intracortical inhibition at the supraspinal level
evoked potentials

(30).

(29)

as well as altered somatosensory

Although Botulinum toxin can enhance some aspects of cortical

activation it fails to improve the impaired activation of the primary motor cortex as seen
in writer's cramp

(31).

When Botulinum Toxin is used to treat painful muscle

hyperactivity disorders frequently substantial pain relief is reported. Pain relief is usually
attributed to the reduction of the muscle hyperactivity. However, formalin-induced pain
in animals can be reduced by Botulinum toxin direct analgesic effect (32). Substance-P is
a neuropeptide involved in pain perception, vasodilatation and neurogenic inflammation.
It has been shown to be blocked by Botulinum toxin together with acetylcholine in the
15

iris muscles of rabbits

(33)

as well as in cultured dorsal root ganglia neurons (34). Direct

Botulinum toxin effect is suggested due to this association of inhibition with a decrease
of SNAP 25.

Botulinum Toxin induced suppression of substance-P has also be

demonstrated in embryonic rat dorsal root ganglia neurons

(35).

When different

Botulinum toxin serotypes were tested, Botulinum Toxin-A produced the strongest
substance-P suppression

(35).

Botulinum Toxin has also been shown to suppress the

release of glutamate, another neurotransmitter involved in nociception, in the periphery
and in the dorsal horn

(36).

This confirmed earlier findings of Botulinum toxin induced

inhibition of glutamate release from cerebrocortical synaptosomes
noradrenalin in PC12 cells

(38),

(37).

The release of

used as a model system for neuronal differentiation, and

calcitonin gene related peptide in autonomic vascular nerve terminals

(39)

could also be

reduced by Botulinum Toxin suggesting additional possible mechanisms for Botulinum
Toxin effects on pain transmission (40).
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Clinical uses for Botulinum Neurotoxin

According to the FDA website, www.fda.gov, information regarding approved
preparations of Botulinum toxin products is limited to 3 preparations of Botulinum
neurotoxin type A. They are marketed by 2 companies under the labels Botox, Botox
Cosmetic and Dysport. The only listed indications for use according to the FDA site are
for cervical dystonia, severe primary axillary hyperhidrosis, strabismus, blepharospasm,
and temporary improvement in the appearance of moderate to severe glabellar lines.
Considerations for health care professionals section states that a boxed warning has been
added to the prescribing information to highlight that Botulinum toxin may spread from
the area of injection to produce symptoms consistent with botulism. Symptoms such as
unexpected loss of strength or muscle weakness, hoarseness or dysphonia, dysarthria, loss
of bladder control, trouble breathing, trouble swallowing, double vision, blurred vision
and drooping eyelids may occur. Swallowing and breathing difficulties can be life
threatening and there have been reports of deaths related to the effects of spread of
Botulinum toxin. It also states that clinical doses expressed in units are not comparable
from one Botulinum toxin product to the next. Units of one product cannot be converted
into units of another product thus Botulinum toxin products differ from one another in
dose units, names, and dosing and are not interchangeable. In November 2001, Health
Canada approved Botox injections to reduce spasticity that can occur after a stroke.
Allison Brashear, MD, professor and chair of the Neurology department at Wake Forest
University Baptist Medical Center in Winston Salem, N. C., directed the first major study
17

in 2002 on the use of Botox for post stroke muscle spasticity

(41).

The results were

published in the New England Journal of Medicine. In that multi-center study, half of the
126 patients received Botox and the other half took a placebo. 62% of the Botox group
reported improvement in the area they desired as opposed to just 27% of the placebo
group. In that study, patients received just one injection. In 2005 at the annual meeting of
the American Association of Physical Medicine in Philadelphia, Dr. Brashear presented
the findings of the first long-term study of the repeated use of Botulinum toxin type-A for
the treatment of post stroke spasticity.

The study focused on 279 patients at 35

rehabilitation centers in Indiana over a 1 year period. The research was funded by the
company that manufactures Botox, Allergen Inc. The participants in the study had hand,
wrist or elbow spasticity. Up to five doses were given to targeted muscles in the wrist,
elbows and fingers.

Six weeks into the study researchers discovered a notable

improvement in patients’ muscle tone from the onset of treatment. Improvement was
graded in four areas consisting of pain, hygiene, dressing and limb posture. At least half
the participants by the end of the study reported that they had improved by one point in
the area they deemed most significant.

Despite these results, treatment for muscle

spasticity remains an off label use. Several other off label uses of Botulinum toxin-A has
been and are currently used in practices of various subspecialties. Some of the more
common off label uses include low back pain, dystonia, laryngeal spasm, hemifacial
spasm and migraine headaches. Since the nature of this study involves treatment using
Botulinum toxin-A for migraine headaches, I will focus on information to that use.
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Supportive Studies
Chronic daily headaches (CDH) are a heterogeneous group of headache disorders
occurring on at least 15 days per month that, according to population studies, affects 4%
to 5% of the general population worldwide (42-45). Chronic migraine is in the subset of the
CDH disorders. Chronic migraine was first characterized by Silberstein and Lipton. By
definition it includes head pain occurring on 15 or more days per month, headache
duration of 4 or more hours and increasing headache frequency with decreasing symptom
severity over a 3-month period

(46-47).

The two most common forms of primary, long

duration CDH disorders are chronic (transformed) migraine and chronic tension
headaches, with most subclassified as transformed migraine

(48-50).

While most CDH

patients are categorized as having transformed migraine others may have chronic tension
type headache

(51-52).

overuse headache

Transformed migraine may also be associated with medication

(53,54).

As indicated previously, the current standard treatment for

migraine headaches includes primarily medications designed to abort an imminent
headache or manage the pain associated with the headache once it starts.

Chronic

migraine is often both common and resistant to treatment even with prophylactic
medications known to be effective in patients with episodic migraine headaches

(55).

Medications used to treat chronic migraines include simple analgesics as well as
prophylactic medications that were originally designed to treat other conditions such as
depression, hypertension, and seizures. Practitioners often struggle with decisions on
how to best manage patients who present with persistent migraine headaches that have
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shown little lasting response to standard medication regimens and are either utilizing
excessive amounts of prescription medications or showing poor response to medications
prescribed with no other explanation as to why their headaches persist. The disability
and impact associated with this disorder is substantial and touches almost every aspect of
the patient's life. These patients experience significantly diminished health-related quality
of life. Mental health as well as physical, social, and occupational functioning may also
be impaired (56). Many alternative methods of management as previously listed also have
had mixed results. Interest in the use of botulinum toxin-A was first generated following
an observation by practitioners using the commercial preparation for cosmetic purposes
following the initial approval by the FDA. When doing procedures involving injections
to remove glabellar lines, patients who had previously experienced frequent migraine
headaches reported a reduction in the frequency and intensity of headaches. Since 1992,
Botulinum toxin-A had been used in purified and diluted form to temporarily paralyze the
Corrugator and Procerus muscles that bring the eye brows together to eliminate wrinkles
in this region. The practice of injecting the area with Botulinum toxin-A in the upper
third of the face for treatment of cosmetic frown lines in patients who coincidentally
suffered from Migraines, resulted in the reported unexpected benifit of migraine relief
(57).

During the November 2-5, 2000 American Society of Dermatologic Surgery meeting

, Richard Glogau, MD, University Of California, San Francisco professor of dermatology
presented a study that he performed at UCSF. He reported that 75 % of patients in his
case study experienced four to six months of Migraine relief following injections of
Botulinum toxin-A into muscles of the face and head. Glogau's small study of 24 patients
added weight to previous reports that Botulinum toxin-A can relieve Migraines.
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Following this opportune discovery, Dr. Glogau and other researchers began to evaluate
injection points and dosages that could alleviate Migraines.

Dr. Glogau's results

indicated that Botulinum toxin-A injected into the muscles of the brow, eyes, forehead,
side of the head and back of the head near the neck provoked sometimes immediate
migraine relief and provided benefit for up to six months. The dosage of Botulinum
toxin-A in his case studies averaged 80 units per patient

(57).

Unfortunately most of the

data at that time consisted of case reports and meeting abstracts. There were no published
randomized double-blind trials that demonstrated safety and efficacy of Botulinum toxinA for treatment of migraines.

There were only two previous studies which were

presented at the 1999 meeting of the American Association for the Study of Headache
(currently the American Headache Society). The first study was reported by researchers
at the Michigan Head Pain and Neurological Institute in Ann Arbor and Michigan State
University.

The study involved a procedure using a one time dose of 25 units of

Botulinum toxin A injected into the muscles of the brow, forehead and side of the head.
The results of this study reflected a reduction in the frequency of Migraines, the severity
of pain, vomiting, and the use of pain medications for up to three months. Treatment with
75-units resulted in migraine relief but also elicited undesirable side effects like eyelid
drooping. In the second study, reported by researchers at the University of California,
Los Angeles, 51% of 96 patients reported complete improvement of their Migraine pain
(57).

Other researchers developed an interest and proceeded to set up their own studies

following these reports of migraine relief using Botulinum toxin-A. In 2004, Stafford
Conway, M.D. et al, undertook an open label study to evaluate the safety and utility of
Botulinum toxin type-A injection therapy for patients with chronic migraine who
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previously had failed to respond to at least three prophylactic medications. The study at
the University of South Alabama Headache Center in Mobile, Al. involved a total of 59
patients. An inclusion criterion was that the patient had previously failed at least three
adequate trials of prophylactic medications known to be effective in treating episodic
migraine.

All participating patients were asked to complete a Migraine Disability

Assessment (MIDAS) questionnaire and to keep a headache diary for the month
preceding Botulinum toxin type-A administration. All patients received 25 units of
Botulinum toxin type-A per the fixed frontal-temporal site protocol published by
Silberstein et al

(58).

Participating patients were asked to return for follow-up 6 weeks

after Botulinum toxin type-A treatment and present their headache diary including any
perceived side effects. Their report included only a descriptive analysis of the results. A
“positive response” was defined to be a 50% or greater reduction in headache days per
month over the last 30 days of the follow-up period relative to the patient’s baseline
status. Other outcome variables analyzed included subjective response (“much better,”
“somewhat better,” “same,” or “worse”) and functionally incapacitating headache days
per month over the last 30 days of the follow-up period relative to the 30 days
pretreatment.

Their results showed a 41% positive response rate however their

conclusion stated that “Based on our observations and results from other published
reports, we offer for speculation the possibility that the current uncertainty regarding the
efficacy of BoNT-A for prevention or suppression of migraine may reflect a type II error;
that is, even the large-scale studies performed to date have involved too few patients
overall and included too many subjects predestined to fail.” One of the most frequently
referenced studies was a multicenter trial funded by Allergan Inc., the makers of Botox
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(BoNT-A ) which was used in the study. This was one of the first randomized, doubleblind, placebo-controlled study of Botulinum toxin type-A in patients with diagnostic
criteria of CDH and was conducted from July 6, 2001, through November 7, 2003, at 28
North American study centers. The study was headed by Stephen D. Silberstein, M.D. in
cooperation with the Bonta-039 Study Group. The study was a randomized, doubleblind, placebo-controlled, parallel group clinical study of 3 fixed-dose treatments of
Botulinum toxin type-A compared with placebo in the treatment of patients with CDH.
Inclusion criteria for the study included men and women aged 18 to 65 years who
experienced headaches on more than 15 days during a 30-day baseline screening period.
Headaches could include any combination of migraines with or without aura, migrainous
headache, probable migraine, and/or episodic or chronic tension-type headaches.
Included were long-term prophylactic headache medications however they had to be
stable with no change in dose or dosing regimen for at least 3 months immediately before
the baseline period. Patients were excluded from the study if they had any medical
condition such as neuromuscular disorders or used any agent that might expose them to
risk if they received Botulinum toxin type-A, had an infection or skin problem at any of
the injection sites, had a known allergy or sensitivity to the study medication or to its
components as well as other exclusions listed in the study

(60).

This was a double-blind

study and neither the investigator nor the patient knew which treatment was given at day
0, day 90, and day 180. Among 1200 screened patients, 702 (mean age 43.4 years with
82.9% female) were enrolled, entered into the placebo run-in period, and subsequently
randomized to active treatment or placebo at day 0. At the end of the placebo run-in
period, of 702 patients, 538 were classified as placebo nonresponders and 164 as placebo
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responders.

Subsequently, patients within each group were randomized to receive

Botulinum toxin type-A at 225 U (n=182), 150 U (n=168), 75 U (n=174), or placebo
(n=178). The primary efficacy end point was the mean change from baseline in the
frequency of headache-free days for the 30-day period ending on day 180 for the placebo
nonresponder group. A secondary efficacy end point was the proportion of patients with a
decrease from baseline of 50% or more in the frequency of headache days per 30-day
period at day 180 for the placebo nonresponder group. Other variables evaluated per 30day period included the frequency of any type of headaches, the proportion of patients
with a decrease from baseline of 50% or more headaches, the frequency of migraine
headaches of any severity, the proportion of patients with a decrease from baseline of
50% or more in migraine headaches, the proportion of patients with a decrease from
baseline of 2 or more migraine headaches, and the frequency of moderate to severe
migraine headaches. Although the primary efficacy end point was not met, Botulinum
toxin type-A treatment in this trial showed a significant difference from placebo in some
analyses. At day 240, the decrease in headache frequency was significantly greater for
the Botulinum toxin type-A 225 U and 150 U groups compared with placebo. The
placebo response was higher than expected but a greater percentage of patients in the
placebo group used pain medications for acute headache throughout the study, thereby
confounding the results

(60).

A later study was published in Headache April 2005 by

Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH
Study Group. This was an 11-month, randomized double-blind, placebo-controlled study
of Botulinum toxin type-A for the treatment of patients aged 18 to 65 years old with 16 or
more headache days per 30 days conducted at 13 North American study centers. The
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primary efficacy measure was the change from baseline in the frequency of headache-free
days in a 30-day period for the placebo nonresponder group at day 180, the chosen
efficacy time point. The secondary efficacy measure was the proportion of patients with a
decrease from baseline of 50% or more in the frequency of headache days per 30-day
period for the placebo nonresponder group at day 180. The change from baseline in the
frequency of headaches per 30-day period, the proportion of patients with a decrease
from baseline of 50% or greater in the frequency of headaches per 30-day period, acute
medication use, and adverse events were also assessed. 355 patients, with a mean age of
43.5 years and 84.5% female, were enrolled and randomized

(59).

At day 180, placebo

nonresponders treated with Botulinum toxin type-A had an improved mean change from
baseline of 6.7 headache-free days per 30 day period compared to a mean change from
baseline of 5.2 headache-free days for placebo-treated patients. The between group
difference was not statistically significant but revealed 1.5 headache-free days in favor of
Botulinum toxin type-A treatment. There was a statistically significant difference was
observed at day 180 endpoint for the secondary efficacy measure. A significantly higher
percentage of Botulinum toxin type-A patients had a decrease from baseline of 50% or
greater in the frequency of headache days per 30-day period at day 180 (32.7% vs.
15.0%, P=.027). The mean change from baseline in the frequency of headaches per 30
day period at day 180 was -6.1 for Botulinum toxin type-A patients vs. -3.1 for the
placebo patients (P=.013). Only 4 of 173 Botulinum toxin type-A patients (2.3%)
discontinued the study due to adverse events

(59).

From the data collected in this study,

the researchers concluded that Botulinum toxin type-A treatment resulted in patients
having, on average, approximately seven more headache free days compared to baseline.
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Although at the primary time point the Botulinum toxin type-A treatment resulted in a 1.5
between-group difference compared to placebo and the difference was determined to be
not statistically significant. The treatment met secondary efficacy outcome measures,
including the percentage of patients experiencing a 50% or more decrease in the
frequency of headache days in addition to statistically significant reductions in headache
frequency. A follow up study using a subgroup analysis of the 11month, randomized
double-blind, placebo-controlled study of Botulinum toxin type-A was later published in
April of 2005. The objective of this study was to assess the efficacy and safety of
Botulinum toxin type A for the prophylaxis of headaches in patients with chronic daily
headache (CDH) without the confounding factor of concurrent prophylactic medications.
This investigation involved data for patients who were not receiving simultaneous
prophylactic headache medication and who constituted 64% of the full study population.
This placebo-controlled study consisted of a 30 day baseline period during which
headache frequency was monitored along with a 30 day single blind placebo run in period
during which response to placebo was determined and a 9 month double blind treatment
period during which patients received three treatment cycles (Botulinum toxin type-A or
placebo) separated by 90 days

(56).

228 patients from the original study group were not

taking prophylactic medication and were included in this analysis. 117 patients received
Botulinum toxin type-A and 111 patients received placebo injections. Mean age was 42.4
± 10.90 years with a mean frequency of headaches per 30 days at baseline of 14.1 for the
Botulinum toxin type-A group and 12.9 for the placebo group ( P = .205). After two
injection sessions, the maximum change in the mean frequency of headaches per 30 days
was -7.8 in the Botulinum toxin type-A group compared with only -4.5 in the placebo
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group ( P = .032). There was a statistically significant between group difference of 3.3
headaches. The between group difference favoring Botulinum toxin type-A treatment
continued to improve to 4.2 headaches after a third injection session ( P = .023).
Botulinum toxin type-A treatment at least halved the frequency of baseline headaches in
over 50% of patients after three injection sessions compared to baseline. Statistically
significant differences between Botulinum toxin type-A and placebo were evident for the
change from baseline in headache frequency and headache severity for most time points
from day 180 through day 270. Only 5 patients (4 patients receiving Botulinum toxin
type-A treatment; 1 patient receiving placebo) discontinued the study due to adverse
events and most treatment related events were transient and mild to moderate in severity.
The researchers concluded that Botulinum toxin type-A is an effective and well-tolerated
prophylactic treatment in migraine patients with CDH who are not using other
prophylactic medications (56).
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Controversy
Although there have been well done studies that have indicated that BoNT has shown
promise in cases of refractory migraine headache treatment and prophylaxis, not
everyone is convinced that the evidence is worthy of FDA approval for routine use. The
primary issue with acceptance of research results showing efficacy of Botulinum toxin
type-A in the treatment of migraine headaches is that the largest studies were funded by
Allergan, the company that produces BoNT. "Official Disability Guidelines" and "ODG"
are trademarks of Work Loss Data Institute. The “Official Disability Guidelines” uses a
comprehensive annual update process based on scientific medical literature review,
survey data analysis, and expert panel validation to determine strength of
recommendation regarding medical procedures. It was designed for use by providers,
employers, insurance claims professionals, and state workers’ compensation authorities.
The large claims review centers use the ODG as a guide to authorize or deny requests for
authorization of procedures on enrolled workers. According to the ODG, “the evidence
is mixed for migraine headaches. This RCT found that both Botulinum toxin type-A
(BoNT-A) and Divalproex sodium (DVPX) significantly reduced disability associated
with migraine, and Botulinum toxin type-A had a favorable tolerability profile compared
with DVPX. (Blumenfeld, 2008). In this RCT of episodic migraine patients, low-dose
injections of BoNT-A into the frontal, temporal, and/or glabellar muscle regions were not
more effective than placebo (Saper, 2007). Botulinum neurotoxin is probably ineffective
in episodic migraine and chronic tension-type headache. (Naumann, 2008)”. In the
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referenced study by Blumenfeld, comparative evaluation of the efficacy and safety of
Botulinum toxin type A and Divalproex sodium as prophylaxis in reducing disability and
impact associated with migraine was done. This was a randomized, double-blind, singlecenter prospective study. Fifty-nine patients received either Botulinum toxin type-A 100
U/placebo-DVPX bid or placebo- Botulinum toxin type-A /DVPX 250 mg bid.
Botulinum toxin type-A /placebo injections were given at Day 0 and at Month 3. Patients
were evaluated at Months 1, 3, 6, and 9.

Both treatments showed significant

improvements in migraine disability scores and reductions in headache days and
headache index. A trend of decreased headache severity was observed with Botulinum
toxin type-A. A greater percentage of DVPX patients reported adverse events possibly
related to treatment (DVPX 75.8% vs. Botulinum toxin type-A 50%, P = .04) and
discontinued because of adverse events (DVPX 27.6% vs Botulinum toxin type-A 3.3%,
P = .012) (61). The second referenced study was done by Saper et al in 2007. This was a
randomized, double-blind, placebo-controlled study of 232 patients with a history of four
to eight moderate to severe migraines per month, with or without aura. Patients were
randomized to placebo or one of four Botulinum toxin type-A groups that received
injections into different muscle regions in the frontal (10 U), temporal (6 U), glabellar (9
U), or all three areas (total dose 25 U). For 3 months following a single treatment,
patients recorded migraine-related variables in a daily diary. Their results indicated that
Botulinum toxin type-A and placebo produced comparable decreases from baseline in the
frequency of migraines (P > or = 0.411). In general, no statistically significant differences
were observed for any efficacy variable. The overall rates of adverse events or treatment
related adverse events were similar among the groups. They concluded that low dose
29

injections of Botulinum toxin type-A into the frontal, temporal, and/or glabellar muscle
regions were not more effective than placebo (62). The third referenced study was done by
Naumann et al in 2008. A literature search was performed including MEDLINE and
Current Contents for therapeutic articles relevant to Botulinum toxin type-A and the
selected indications. They concluded by their research that Botulinum toxin type-A is
probably ineffective in episodic migraine and chronic tension-type headache. There is
presently no consistent or strong evidence to permit drawing conclusions on the efficacy
of Botulinum toxin type-A in CDH mainly transformed migraine (63).
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Recent Data
In September 2008, Allergan announced that it had completed analyzing data of two
Phase III clinical trials designed to evaluate the use of botulinum toxin type-A for the
prophylactic treatment of headache in adults suffering from chronic migraine as defined
by the criteria of chronic daily headaches. In the two Phase III clinical trials, patients
were randomly assigned for treatment with botulinum toxin type-A or placebo injections
every 12 weeks. The primary analysis was performed at week 24 following 2 treatment
cycles. The two major efficacy measures evaluated in the trials were change from
baseline in the number of headache episodes and number of headache days occurring in
the 28 day period preceding the week 24 time point. In the first Phase III clinical trial,
Allergan prospectively selected number of headache episodes as the primary endpoint for
evaluation. Number of headache days was selected as the major secondary endpoint.
Results from the first Phase III clinical trial indicated that although both the botulinum
toxin type-A and placebo treatment groups showed a statistically significant improvement
from baseline.

There was no significant difference in the reduction of number of

headache episodes between patients receiving botulinum toxin type-A and placebo. As in
previous study outcomes, the study did show a decrease in number of headache days
which is the FDA's preferred efficacy measure. This was significantly greater in patients
receiving botulinum toxin type-A as compared to patients receiving placebo (p=0.006).
The decrease in number of migraine or probable migraine days was also found to be
significantly greater in patients treated with botulinum toxin type-A as compared to
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patients receiving placebo (p=0.002). Based on the data from the first Phase III clinical
trial, the primary endpoint for the second Phase III study was prospectively changed to
number of headache days, with number of headache episodes changed to a secondary
endpoint, before the data were unmasked. In the second Phase III study, the primary
endpoint and key secondary endpoints showed statistically significant benefit of
botulinum toxin type-A treatment over placebo injections. The patients treated with
botulinum toxin type-A demonstrated a significantly greater decrease in both number of
headache days (p<0.001) and number of headache episodes (p=0.003). As in the first
Phase III trial, the second study also showed a decrease in number of migraine or
probable migraine days that was significantly greater in patients treated with botulinum
toxin type-A as compared to placebo (p<0.001).

In both Phase III clinical trials,

botulinum toxin type-A treatments were well tolerated in patients suffering from chronic
migraine. Both studies used quality of life evaluation using the validated Headache
Impact Test which is a migraine management tool to help identify the severity and
frequency of migraine headaches. Patients receiving botulinum toxin type-A treatments
scored statistically significantly higher improvement in quality of life when compared to
patients receiving placebo injections (p<0.001 in both studies). Allergan is in the process
of gaining approval from the FDA to add the use of botulinum toxin-A for treatment of
chronic migraine headaches based on this new data.
sponsored by Allergan produced similar results (64).
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Other recent smaller studies

MIDAS Questinnaire
Despite the lack of support by the FDA, numerous practitioners as including those in
some VA hospitals perform botulinum toxin-A injections for prophylactic treatment of
refractory chronic megraine headaches. Both the Neurology Department at Bay Pines
Hospital in St. Petersburg, Fl and the Neurology Department’s Pain Management Clinic
at James A Haley VA Hospital in Tampa, Fl provide this service. From observation and
evaluation of the patients undergoing the procedure, it appeared that there was a general
positive response to the treatment and overall patient satisfaction. Unfortunately there
was no documentation to quantitate the effect on the patient’s improvement in lost work
days, ability to perform activities of daily living, increase or decrease in medication use
as well as cost difference pre and post treatment and effect on activities of daily living.
One of the tools for evaluation of the severity of a patient’s disability due to the effects of
migraine headaches is the Migraine Disability Assesment (MIDAS) questionairre. The
MIDAS questionnaire was put together to help measure the impact migraine headaches
have on the patient’s life over the 3 months prior to the interview by the physician
administering it. The primary intent was to assess headache-related disability with the
aim of improving migraine care. Headache sufferers answer five questions scoring the
number of days in the past 3 months related to activity limitations due to migraine. The
internal consistency, test–retest reliability, and validity of the questionnaire were assessed
in separate population based studies of migraine sufferers. The face validity, ease of use,
and clinical utility of the questionnaire were evaluated in a group of 49 physicians who
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independently rated disease severity and need for care in a diverse sample of migraine
case histories. The test–retest Pearson correlation coefficient for the total MIDAS score
was approximately 0.8. The MIDAS score was valid when compared with a reference
diary based measure of disability. The overall correlation between MIDAS and the diary
based measure was 0.63. The MIDAS score was also correlated with physicians’
assessments of need for medical care (r = 0.69). From studies completed to date, the
MIDAS Questionnaire has been shown to be internally consistent, highly reliable, valid,
and correlates with physicians’ clinical judgment. These features support its suitability for
use in clinical practice. Use of the MIDAS Questionnaire may improve physician patient
communication about headache related disability and may favorably influence health care
delivery for migraine patients

(66).

Though the questionnaire has been validated by the

American Academy of Neurology, it only gives information regarding the severity of the
patient’s disability prior to care by the physician giving it. The questionnaire does not
address other issues such as direct or indirect cost of treating migraine headaches. In a
2005 study done by Goldberg, migraine headaches were estimated to result in annual
costs totaling as much as $17 billion in the United States (67). Most of the direct costs are
for outpatient services such as medications, office visits, emergency department visits,
laboratory/diagnostic services and management of treatment side effects. Indirect costs
from lost productivity in the workplace, as previously discussed, add substantially to the
total. The Triptan class of drugs, used for abortive treatment, account for the greatest
portion of medication costs. Research suggests that a stratified care strategy, with initial
therapy based on the patient’s score on the MIDAS scale, is both clinically advantageous
and more cost effective than stepped care strategies. It should be noted that the Triptans
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are not interchangeable and costs as well as clinical outcomes may vary with different
agents in this class. Migraine prophylaxis is aimed at preventing frequent attacks and the
development of a long term condition that often incurs heavy costs for abortive treatment,
diagnostic services, and medical care. Agents approved for migraine prophylaxis include
those listed in the above previous discussion. As with abortive therapy, costs vary widely
among these prophylactic agents. Of the total annual cost associated with migraine and its
treatment, roughly $1.5 billion goes to medication with Triptans accounting for $1.18
billion with a mean cost per prescription of $160

(68).

Focusing specifically on migraine

headaches, another study found that the annual cost to employers exceeded $14.5 billion,
of which $7.9 billion was due to absenteeism, $5.4 billion to diminished productivity, and
$1.2 billion to medical costs

(69).

A small open label trial of Botulinum toxin was

conducted in 5 patients with migraine headaches that were unresponsive to conventional
antimigraine medications. Evaluation was done after 1 year of injections at 3 month
intervals. The use of other migraine medications, as measured by the change in annual
costs for other medications, had decreased from pretreatment levels. When the cost of the
Botulinum toxin-A treatment itself was included, the total change in annual medication
cost ranged from an increase of $648 to a decrease of $2717. All of the patients showed
substantial clinical improvement with no reported adverse events. Migraine symptoms
typically decreased within a few days after each injection and maximal effects were noted
over the 2 months after treatment

(70).

A budgetary model provided a theoretical basis

for predicting the cost outcome of selecting a given approach to migraine management.
This model focused on the use of Botulinum toxin-A for prophylaxis in chronic migraine
patients enrolled in a commercial managed care plan. The goal was to assess the impact
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of a decision to allow the use of Botulinum toxin, in terms of cost effect for the plan as a
whole. In calculating the cost of prophylaxis with Botulinum toxin, treatment at a
standard interval of 3 months means that patients would receive 4 treatments per year.
With the cost of each treatment given as $521.25, the yearly cost per patient is $2085,
and the total yearly cost for 240 patients was $500,400. The model did not account for a
decrease in emergency department visits and hospitalization as a result of effective
migraine prophylaxis which would be expected to augment the savings. Offsetting these
costs would be a reduction in the amount of headache medication used for abortive
treatment

(70).

The final cost difference according to the study by Goldberg is that “in a

plan with 1 million members, the savings associated with migraine prophylaxis using
Botulinum toxin represents a change of less than 1 cent in overall cost per member per
month ($76 360 divided by 12 million member months is a reduction of approximately
$0.006 per member per month). The point, however, is not the insignificant change in
cost, but that superior clinical outcomes in migraine management can be obtained with no
increase in cost” (67). According to the results of his study, headache related visits to the
office and emergency department were reduced by 32% and 49% respectively. These
reductions in headache related visits resulted in a net savings of $18,757. The greatest
clinical improvements were seen in patients whose conditions were most severe at
baseline (72).
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Study Protocol
Having an interest in the patient’s response to treatment with Botulinum toxin-A for
migraine headache prophylaxis, this study utilized the questions in the MIDAS
questionnaire with a slight modification to assess the patient’s post treatment response.
In addition to the original 7 questions on the questionnaire, additional information
regarding medication usage pre and post treatment as well as assessment of functional
ability pre and post and number of treatments. The study is designed as a cross sectional
survey of patients currently undergoing the procedure at James A. Haley VA Medical
Center Department of Neurology Pain Clinic and Bay Pines VA Hospital Department of
Neurology outpatient clinic.

Inclusion criteria were patients age 21 – 65 who had

received at least 2 treatments. The patients currently undergoing the treatment with
Botulinum toxin-A were pre screened by each department, on initial evaluation when first
presenting to each clinic, to fit the criteria of chronic daily headaches as previously
referenced and demonstrated a history of failure to other standard treatment protocols.
Since the standard time between each treatment is typically 3-4 months, the questionnaire
was to be administered over a 60 day period once initiated to prevent duplication of
patient responses. No personal health information was required on the questionnaire and
exemption was granted for informed consent and HIPPA requirements.

The study

objective is to assess patient reported efficacy of Botulinum toxin-A for the prophylaxis
of Migraine headaches in patients with frequent Migraine headaches prior to initiation of
treatment with Botulinum toxin-A compared to post treatment. The research plan as
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previously discussed is to present questions addressing the patient status prior to the
initiation of treatment as well as post treatment. Patient quality of life change, duration
and frequency headache improvement are the primary focus.

Other considerations

included the cost difference between the previous use of other treatment and the periodic
treatment with botulinum toxin-A. Methodology is a cross sectional study utilizing a
questionnaire consisting of a modified Migraine Disability Assessment (MIDAS)
questions were given to patients by the principle investigator or a significant member of
the study who has undergone the required privacy training. Qualified patients are those
who had received at least two series of injections. New patients who have not yet
received treatment are excluded. The patients are currently under treatment at both Bay
Pines VA neurology in St Petersburg, Fl and James A Haley VA pain clinic in Tampa, Fl.
Patients who reported chronic Migraine headaches and were refractory to previous
treatment methods were screened and placed in programs utilizing intramuscular
injection of Botulinum toxin-A at standard points on the face, Temporalis muscle and
paracervical muscles. The study’s anticipated impact and significance relate to the fact
that patients that are debilitated by recurrent chronic migraine headaches suffer loss of
productive time at work and home. Treatment with Botulinum toxin-A may results in
significant relief allowing fewer days lost at work and improved quality of life. There
may be significant cost saving if treatment results in discontinuation of other medications
previously used for treatment of migraine headaches or decreased use of hospital and
emergency department facilities. This study utilizes a questionnaire consisting of a
modified Migraine Disability Assessment (MIDAS) questions will be given to patients
who had received more than one series of injections. Included in the study are Male or
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Female veterans age 21 – 65 currently under treatment with Botulinum toxin-A for
migraine headache prophylaxis. Exclusion criteria consist of patients less than 21 years
of age, initial treatment, over 65 years of age or physician clinical judgment for
exclusion. Questionnaire filled out by the patient or by one of the attending physicians
with proper privacy training with no personal health information on the form and
voluntary participation as outlined on the cover sheet. Statistical analysis through patient
response to a standardized questionnaire with weighted responses. Classification is based
on existing patients currently undergoing care at the 2 neurology clinics who have
already been screened to qualify for the procedure by the respective departments. The
study is designed to extend no longer than 60 days following the start of initiating the
questionnaire to prevent duplication of responses. This is assured since the patient
treatment is no more frequent than every 90 – 120 days.
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Data Collection and Analysis
Patients at both James A Haley VA Department of Neurology Pain Clinic and Bay Pines
Neurology Clinic who were currently undergoing treatment for migraine headaches with
Botulinum toxin-A were randomly presented with the survey.

The patients were

screened per protocol to meet the criteria for the study. Since the patients were already
undergoing treatment with Botulinum toxin-A for persistent refractory migraine
headaches, they were already presumed to fit the definition of chronic daily headaches.
Due to unplanned inconsistency in offering the questionnaire to the patients, the qualified
respondents were randomly chosen and answered the survey. A total of 46 patients were
surveyed at both Bay Pines VA and James A Haley VA. 19 patients were being treated at
Bay Pines VA Neurology Clinic and 27 were under care at James A Haley VA
Department of Neurology Pain Clinic. Of the 46 total patients surveyed, 10 were female
and 36 were male. Due to IRB concerns at Bay Pines VA, the age variable was not
recorded on surveys that were filled out in the Neurology Department there. Gender was
recorded at both facilities as previously noted. The questions were graded according to
responses to days affected by headache for 3 months prior to initiation of treatment and
compared to responses of the same question modified to reflect the patient’s condition for
3 months following at least one treatment. The first question of the questionnaire relates
to the affect of migraine headaches on the patient’s work. The second question relates
lost work productivity.

Question three asks about the ability of the patient to do

housework during their migraine episodes. Similarly question four relates to interference
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and decreased ability to effectively do housework, but not prevent it, due to migraine
episodes. The fifth question asks about how the headache would interfere with family or
social events. The 2 following questions labeled A and B on the MIDAS questionnaire
were designated as 6 and 7 on the study pre and post questionnaire. They request the
patient’s assessment of frequency of headaches in days over the previous three months
and severity of headaches as graded on a scale of 1 – 10. The MIDAS grading system
contains a scale from I – IV. For simplicity purposes and data analysis, these are
designated as 1 – 4 when interpreting the responses on the questionnaire (Table 1).
Responses to questions 1 – 5 are converted from number of days reported to appropriate
MIDAS grading scores. Since cost of treatment is a component of this study, section 8
asks additional questions regarding use of medications for treatment of migraine
headaches pre and post Botulinum toxin-A. Question 9 asks the patient to assess the
quality of life prior to and after treatment with Botulinum toxin-A. The final question on
the post treatment questionnaire refers to the total number of treatments that the patient
has had.
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Table 1
Grade

Definition

Days

Grade 1

Minimal or Infrequent Disability

0-5

Grade 2

Mild or Infrequent Disability

6-10

Grade 3

Moderate Disability

11-20

Grade 4

Severe Disability

21+
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Results
The mean age of the patients surveyed was confined to responses from James A Haley
VA only due to the previously mentioned issues with Bay Pines VA IRB. Among those
surveyed, the mean age was 51.8 with a range from 30 to 65 years of age. The ratio of
males to females surveyed at both facilities was 3.6:1. Comparisons of responses to
questions 1- 9 were analyzed using paired T-test, with the patient’s pre-treatment status
as the control, and Wilcoxon Signed Ranks Test. In Table 2 we see the results of paired
samples statistics for questions 1 – 5. In response to question 1 regarding disability
relating to the frequency of lost work days, the mean level of disability as indicated by
the MIDAS score is reduced overall for the 46 respondents from a score of Grade 2 to
Grade 1 with a mean reduction of .957 (Table 4). 95% confidence interval was .626 to
1.288 with a T-score of 5.82. When evaluating the results by Wilcoxon Signed Ranks
Test, the number of patients who indicated a reduction in overall disability days is equal
to those who indicated no change (Table 13).

In analyzing the effect on interference

with productivity at work, response to question 2 resulted in an overall mean reduction
from Grade 3 to Grade 1. There was a mean reduction of 1.391 with a 95% confidence
interval of 1.051 to 1.731 and a T-score of 8.244. Wilcoxon Signed Ranks Test revealed
32 respondents indicated a reduction in disability with 14 respondents indicating no
change. In order to evaluate the effect that migraine headaches have on activities of daily
living, question 3 asks how often the patient was prevented from performing daily
housework. Assessment of the responses reveals a reduction overall from Grade 3 to
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Grade 1 with a mean reduction of 1.28 at a 95% confidence interval of .947 to 1.618 and
a t-score of 7.707 (Table4). Wilcoxon Signed Ranks Test analysis indicated that there
were 31 respondents that reported a reduction in disability days and 15 that indicated no
change (Table 13). Overall days where productivity was diminished regarding activities
of daily living were addressed in question 4. The response indicated that there was an
overall reduction from Grade 3 to Grade 1with a mean reduction of 1.457 at a 95%
confidence interval of 1.088 to 1.825 with a t score of 7.954. Wilcoxon Signed Ranks
Test analysis indicated 32 respondents had a reduction in MIDAS score while 13 had no
change and 1 patient reported an actual increase in MIDAS score. The effect on social
life and family activities is another area of concern which is addressed in question 5.
According to the respondents there was a reduction in disability score from Grade 3 to
Grade 1 with a mean reduction of 1.174 at 95% confidence interval of .829 to 1.519 with
a T-score of 6.860. Wilcoxon Signed Ranks Test analysis reveals 28 respondents with a
reduction in MIDAS score and 18 with no change in social or family activities. Question
6 asks the patient to record how many headaches they had in the 3 months prior to
initiation of treatment and 3 months prior to the questionnaire post botulinum toxin-A
treatment. Analysis of the responses demonstrates that there is a mean reduction of
41.957 headache days with a 95% confidence interval of 32.936 to 50.977 and a T-score
of 9.368(Table 7). Wilcoxon Signed Ranks Test analysis reveals 42 patients reporting a
reduction in frequency of headaches and 4 reporting no change (Table 16). Patients were
asked to rate the severity of their headaches in question 7 based upon a standard scale of
0 – 10 with 0 being no pain and 10 being pain as bad as it could be. Analysis of the
responses shows that there is an overall reduction of pain scores from a mean of 8.85
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prior to treatment to 5.09 post treatment (Table 5) giving a mean reduction of 3.76 at a
95% confidence interval of 3.03 to 4.49 with a T-score of 10.368 (Table 5-7) . Wilcoxon
Signed Ranks Test analysis reveals 40 patients reporting a reduction in the severity of
their headaches, 1 reporting an increase in severity and 5 indicating no change in
headache severity (Table 16). There is a lot of variability when evaluating medication
usage. The type of medication used can vary greatly in price and frequency of usage. To
simplify this, medications were placed on general categories. Weekly acetaminophen
usage, as reflected in Tables 8-10, appeared to be reduced post treatment from a mean of
11.74 to 2.20 (Table 8) with a mean reduction of 9.04 at a 95% confidence interval
between 1.476 to 16.611 and a T-score of 2.407 (Table 10). A breakdown of usage by
Wilcoxon Signed Ranks Test analysis reveals 18 patients reporting a reduction, 26
patients indicating no change and 2 patients indicating an increase in usage (Table 17).
General use of NSAIDs also showed reduction in use post treatment from a mean of
12.67 to 1.91 with a mean reduction of 10.761 at a 95% confidence interval between
4.518 to 17.004 and a T-score of 3.471. Wilcoxon Signed Ranks Test analysis indicates
20 patients reported a decrease in use, 1 increase in usage and 25 with no change in use.
Use of opiates showed a decrease from a mean of 7.80 to 3.39 with a mean reduction of
4.413 at a 95% confidence interval between 1.743 to 7.083 and a T-score of 3.329.
Wilcoxon Signed Ranks Test analysis shows 19 patients with a decrease in weekly use, 2
with an increase and 25 with no change in weekly use. Weekly Triptan use was reduced
from a mean of 1.22 to .52 with a mean reduction of .696 at a 95% confidence interval of
2.24 to 1.168 and a T-score of 2.968. Wilcoxon Signed Ranks Test analysis reveals 14
patients reporting a decrease, 1 reporting an increase and 31 with no change (Table 18).
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Response to use of psychotropic medications for treatment of migraine headaches
showed a mean reduction from 3.54 to 1.24 with a mean reduction of 2.28 at a confidence
interval of .528 to 3.983 and a T-score of 2.704. Wilcoxon Signed Ranks Test analysis
indicates 11 patients with an increase in weekly use and 35 with no change. Other
medications can consist of a wide variety including Ergotamines and Tramadol. The
responses from the 46 patients reveal a mean reduction in weekly use from 2.54 to 1.70
with a mean reduction of .848 at a 95% confidence interval of -1.351 to 3.047 and a Tscore of .776. Wilcoxon Signed Ranks Test analysis shows 9 patients reporting a
reduction, 2 with an increase in use and 35 with no change in weekly usage. Overall
quality of life showed an increase from a mean score of 3.20 to 7.17 (Table 11) with a
mean improvement of 3.978 at a 95% confidence interval of -4.746 to -3.210 and a Tscore of -10.433 (Table 13). Wilcoxon Signed Ranks Test analysis shows 1 patient
indicating a decrease in quality of life, 41 indicating an improvement and 4 with no
change (Table 19). Of the 46 patients responding to the questionnaire, 40 responded to
the final question of number of treatments. The mean of those who responded was 10.2.
Figures 1 – 14 graphically represent the pre and post responses of each patient to the
questions on the survey.
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Paired Sample Tests
Table 2

Pair 1

Pair 2

Pair 3

Pair 4

Pair 5

Paired Samples Statistics
Mean

N

Std. Deviation

Std. Error Mean

Pre1

2.20

46

1.222

.180

Post1

1.24

46

.766

.113

Pre2

2.72

46

1.167

.172

Post2

1.33

46

.790

.117

Pre3

2.67

46

1.194

.176

Post3

1.39

46

.930

.137

Pre4

2.72

46

1.223

.180

Post4

1.26

46

.648

.095

Pre5

2.46

46

1.295

.191

Post5

1.28

46

.688

.102

Table 3

Paired Samples Correlations
N

Correlation

Sig.

Pair 1

Pre1 & Post1

46

.448

.002

Pair 2

Pre2 & Post2

46

.367

.012

Pair 3

Pre3 & Post3

46

.458

.001

Pair 4

Pre4 & Post4

46

.235

.115

Pair 5

Pre5 & Post5

46

.450

.002
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Table 4

Paired Samples Test
Paired Differences
95% Confidence
Interval
of the Difference
Std.
Std.
Error
Mean Deviation Mean
1.115

Lower

.164

Upper

df

5.820

45

.000

8.244

45

.000

Pair
1

Pre1 Post1

.957

Pair
2

Pre2 Post2

1.391

Pair
3

Pre3 Post3

1.283

1.129

.166

.947

1.618 7.707

45

.000

Pair
4

Pre4 Post4

1.457

1.242

.183

1.088

1.825 7.954

45

.000

Pair
5

Pre5 Post5

1.174

1.161

.171

.829

1.519 6.860

45

.000

1.145

Table 5

.626

t

Sig.
(2tailed)

.169

1.051

Pair 2

1.731

Paired Samples Statistics

Mean
Pair 1

1.288

Std.
Deviation

N

Std. Error
Mean

Pre6

62.89

62.89

46

29.411

4.336

Post6

20.93

20.93

46

25.404

3.746

Pre7

8.85

8.85

46

1.095

.161

Post7

5.09

5.09

46

2.439

.360
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Table 6

Paired Samples Correlations
N

Correlation

Sig.

Pair 1

Pre6 &
Post6

46

.393

.007

Pair 2

Pre7 &
Post7

46

.205

.172

Table 7

Paired Samples Test
Paired Differences
95% Confidence
Interval of the
Difference

Pair 1

Pre6 -

Std.
Error
Mean

Sig.
(2tailed)

Mean

Std.
Deviation

41.957

30.376

4.479

32.936

50.977

9.368

45

.000

3.761

2.460

.363

3.030

4.491

10.368

45

.000

Lower

Upper

t

df

Post6
Pair 2

Pre7 Post7
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Table 8

Paired Samples Statistics

Mean
Pair 1

Pair 2

Pair 3

Pair 4

Pair 5

Pair 6

Std.
Deviation

N

Std. Error
Mean

Tyl Pre

11.74

46

24.848

3.664

Tyl Post

2.70

46

6.073

.895

12.67

46

21.170

3.121

NSAID
Post

1.91

46

4.273

.630

Opiate Pre

7.80

46

11.299

1.666

Opiate Post

3.39

46

8.131

1.199

Triptan Pre

1.22

46

2.021

.298

Triptan
Post

.52

46

.752

.111

PSY Pre

3.52

46

6.595

.972

Psy Post

1.24

46

3.484

.514

Other Pre

2.54

46

6.735

.993

Other Post

1.70

46

6.759

.997

NSAID Pre
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Table 9

Paired Samples Correlations
N

Correlation

Sig.

Pair 1

Tyl Pre & Tyl Post

46

.016

.914

Pair 2

NSAID Pre & NSAID Post

46

.135

.371

Pair 3

Opiate Pre & Opiate Post

46

.615

.000

Pair 4

Triptan Pre & Triptan Post

46

.698

.000

Pair 5

PSY Pre & Psy Post

46

.497

.000

Pair 6

Other Pre & Other Post

46

.398

.006
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Table 10

Paired Samples Test
Paired Differences
95%
Confidence
Interval of the
Difference

Mea
n

Std.
Devia
tion

Std.
Error
Mean

Lower

Uppe
r

t

df

Sig.
(2taile
d)

Pair
1

Tyl Pre - Tyl
Post

9.04
3

25.48
3

3.757

1.476

16.61
1

2.4 45
07

.02
0

Pair
2

NSAID Pre NSAID Post

10.7
61

21.02
4

3.100

4.518

17.00
4

3.4 45
71

.00
1

Pair
3

Opiate Pre Opiate Post

4.41
3

8.990

1.326

1.743

7.083

3.3 45
29

.00
2

Pair
4

Triptan Pre Triptan Post

.696

1.590

.234

.224

1.168

2.9 45
68

.00
5

Pair
5

PSY Pre Psy Post

2.28
3

5.726

.844

.582

3.983

2.7 45
04

.01
0

Pair
6

Other Pre Other Post

.848

7.406

1.092

-1.351

3.047

.77 45
6

.44
2
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Table 11

Paired Samples Statistics
Mean

Pair 1

Table 12

N

Std. Error Mean

PreQual

3.20

46

1.614

.238

PostQual

7.17

46

2.069

.305

Paired Samples Correlations
N

Pair 1

Std. Deviation

PreQual & PostQual

Table 13

Correlation

46

Sig.

.030

.846

Paired Samples Test
Paired Differences
95%
Confidence
Interval of the
Difference

Std.
Std.
Error
Mean Deviation Mean Lower Upper
Pair PreQual
1
3.978
PostQual

2.586

.381 -4.746
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t

Sig.
(2df tailed)

- 45
3.210 10.433

.000

Wilcoxon Signed Ranks Test
Table 14:

Ranks
N

Post1 – Pre1

Post2 – Pre2

Mean Rank

Sum of Ranks

Negative Ranks

23a

12.00

276.00

Positive Ranks

0b

.00

.00

Ties

23c

Total

46

Negative Ranks

32d

16.50

528.00

Positive Ranks

0e

.00

.00

Ties

14f

Total

46

a. Post1 < Pre1; b. Post1 > Pre1; c. Post1 = Pre1
d. Post2 < Pre2; e. Post2 > Pre2; f. Post2 = Pre2
Test Statisticsb
Post1 - Pre1
Z
Asymp. Sig. (2-tailed)

Post2 - Pre2
-4.256a

-5.004a

.000

.000

a. Based on positive ranks. b. Wilcoxon Signed Ranks Test
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Table 15:

Ranks
N

Post3 - Pre3

Post4 - Pre4

Post5 - Pre5

Mean Rank

Sum of Ranks

Negative Ranks

31a

16.00

496.00

Positive Ranks

0b

.00

.00

Ties

15c

Total

46

Negative Ranks

32d

17.36

555.50

Positive Ranks

1e

5.50

5.50

Ties

13f

Total

46

Negative Ranks

28g

14.50

406.00

Positive Ranks

0h

.00

.00

Ties

18i

Total

46

a. Post3 < Pre3; b. Post3 > Pre3; c. Post3 = Pre3; d. Post4 < Pre4; e. Post4 > Pre4; f.
Post4 = Pre4; g. Post5 < Pre5; h. Post5 > Pre5; i. Post5 = Pre5
Test Statistics b
Post3 - Pre3
Z

Post4 - Pre4

Post5 - Pre5

-4.928a

-4.983a

-4.687a

.000

.000

.000

Asymp. Sig. (2-tailed)

a. Based on positive ranks. b. Wilcoxon Signed Ranks Test
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Table 16:

Ranks

N
Post6 - Pre6

Post7 - Pre7

Mean Rank

Sum of
Ranks

Negative Ranks

42a

21.50

903.00

Positive Ranks

0b

.00

.00

Ties

4c

Total

46

Negative Ranks

40d

21.38

855.00

Positive Ranks

1e

6.00

6.00

Ties

5f

Total

46

a. Post6 < Pre6; b. Post6 > Pre6; c. Post6 = Pre6; d. Post7 < Pre7; e. Post7 > Pre7;
f. Post7 = Pre7
Test Statistics b
Post6 - Pre6
Z
Asymp. Sig. (2-tailed)
a. Based on positive ranks. b. Wilcoxon Signed Ranks Test
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Post7 - Pre7

-5.647a

-5.521a

.000

.000

Table 17:

Ranks
N

Tyl Post - Tyl
Pre

NSAID Post NSAID Pre

Opiate Post Opiate Pre

Mean Rank

Sum of Ranks

Negative Ranks

18a

10.11

182.00

Positive Ranks

2b

14.00

28.00

Ties

26c

Total

46

Negative Ranks

20d

11.50

230.00

Positive Ranks

1e

1.00

1.00

Ties

25f

Total

46

Negative Ranks

19g

11.00

209.00

Positive Ranks

2h

11.00

22.00

Ties

25i

Total

46

a. Tyl Post < Tyl Pre; b. Tyl Post > Tyl Pre; c. Tyl Post = Tyl Pre; d. NSAID Post <
NSAID Pre; e. NSAID Post > NSAID Pre; f. NSAID Post = NSAID Pre; g. Opiate
Post < Opiate Pre; h. Opiate Post > Opiate Pre; i. Opiate Post = Opiate Pre.
Test Statistics b
Tyl Post - Tyl
Pre
Z
Asymp. Sig. (2-tailed)

NSAID Post NSAID Pre

Opiate Post Opiate Pre

-2.876a

-3.982a

-3.258a

.004

.000

.001

a. Based on positive ranks. b. Wilcoxon Signed Ranks Test
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Table 18:

Ranks
Mean
Rank

N
Triptan Post - Triptan Pre

Psy Post - PSY Pre

Other Post - Other Pre

Sum of
Ranks

Negative Ranks

14a

8.32

116.50

Positive Ranks

1b

3.50

3.50

Ties

31c

Total

46

Negative Ranks

11d

6.00

66.00

Positive Ranks

0e

.00

.00

Ties

35f

Total

46

Negative Ranks

9g

5.83

52.50

Positive Ranks

2h

6.75

13.50

Ties

35i

Total

46

a. Triptan Post < Triptan Pre; b. Triptan Post > Triptan Pre; c. Triptan Post = Triptan
Pre; d. Psy Post < PSY Pre; e. Psy Post > PSY Pre; f. Psy Post = PSY Pre; g. Other
Post < Other Pre; h. Other Post > Other Pre; i. Other Post = Other Pre.
Test Statistics b
Triptan Post Triptan Pre
Z

Psy Post Psy Pre

Other Post Other Pre

-3.255a

-3.207a

-1.746a

.001

.001

.081

Asymp. Sig. (2-tailed)

a. Based on positive ranks. b. Wilcoxon Signed Ranks Test
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Table 19:

Ranks
N

PostQual PreQual

Mean Rank

Sum of Ranks

Negative Ranks

1a

17.50

17.50

Positive Ranks

41b

21.60

885.50

Ties

4c

Total

46

a. PostQual < PreQual; b. PostQual > PreQual; c. PostQual = PreQual
Test Statistics b
PostQual - PreQual
-5.444a

Z
Asymp. Sig. (2-tailed)

.000

a. Based on negative ranks. b. Wilcoxon Signed Ranks Test.
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Conclusion
According to the patients’ response to this survey, it appears that there was an overall
improvement in the patients’ ability to do work, for those who were employed, as well as
their ability to do activities of daily living post treatment with Botulinum toxin-A. From
the patients’ response there was an approximate 67% decrease in the mean frequency of
headaches over the surveyed pre and post 3 month periods. The intensity of headaches
also demonstrated a mean decrease from approximately 9/10 to 5/10 from pre to post
treatment. When estimating the cost of treatment, prices for each class of medication
were calculated using an estimated average for the prescription strength of each class of
medication. The estimated cost of Acetaminophen 325mg is about $.17 per capsule.
Having a mean reduction in weekly use of approximately 9 pills doesn’t really amount to
a tremendous cost saving and over a 3 month period it would translate to approximately
$18.36 saved. Similarly inexpensive are NSAIDs. At an average price using the most
commonly prescribed/recommended NSAIDs (Ibuprofen 800mg, Naproxen 500mg,
Nabumetone 750mg and Fiorinal 50/325/40), the average price per pill is $1.66. There
was a mean reduction of 10.76 pills per week according to the survey responses. This
translates to a weekly reduction of $17.87 and a 3 month saving of approximately
$214.36. Mean weekly opiate use reduction was 4.413. At and average cost of the most
commonly prescribed narcotic analgesics (Hydrocodone, Oxycodone, Meperidine as well
as combination with non narcotic analgesics) of $2.41 per pill, the overall savings for the
3 month period would be estimated at $127.62. The most expensive medications of this
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survey were the Triptans. Using an average per dose price for the most commonly
prescribed of this group (Maxalt, Imitrex and Zomig), the average price per oral dose was
approximately $26.53. With a mean reduction of .696 per week at a 3 month time frame,
the estimated cost saving would be $221.58. The use of psychotropic medications, such
as Trazadone 100mg, Amitryptyline 50mg and Divalproex sodium 250mg, was estimated
at an average price of $2.34 per pill. Calculation of 3 month use was reduced by a mean
weekly drop of 2.253 results in a saving of $63.26.

There are numerous other

medications that are used to treat migraine headaches however for simplicity purposes I
chose to evaluate Tramadol 50mg and Cafergot 1-100. The average price per dose for
these two medications is approximately $2.67. With a mean weekly reduction of .848,
the 3 month saving would translate to approximately $27.17. The cost of each treatment
with Botulinum toxin A for the VA facilities participating in this study is about $400.00.
There was a reported mean increase in overall quality of life from 3.20 to 7.17 on the
scale of 0 (non functional) to 10 (excellent). When interviewing the patients the majority
of those responding indicated overall satisfaction with their treatment. The mean number
of treatments was 10.2.
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Discussion
When interpreting the results of the respondents to this survey, a few concerns come to
mind. The first thought is that I was unable to evaluate responses from patients who may
have had adverse response or stopped treatment due to lack of response. There is also
some technical difficulty in ensuring that the response only involves information relating
to migraine headache and not other chronic pain conditions that may also coexist. Also
when evaluating pain medication usage, limiting responses only to those medications
used for the treatment of migraine headaches proved challenging since some medications
were used for other chronic pain conditions concurrently. It is difficult to get an accurate
cost analysis since there is a tendency to have multiple prescription medications and over
the counter medications used in efforts to treat and prevent chronic migraine headaches.
Also the cost of the medications, particularly Triptans, will vary greatly according to the
route administered.

Another cost factor that was occasionally revealed by the

respondents is the frequency of visits to the emergency room for treatment of migraine
headaches. Though it was not evaluated by this study, some of the respondents did reveal
frequent visits to the emergency room which they indicate were reduced or eliminated
post treatment. Overall it appears that the use of Botulinum toxin-A in the treatment of
migraine headaches does have some clinical value and can possibly be used in refractory
cases to help increase the patients functional capacity and possibly reduce the cost of
treatment by reducing multiple prescription medication use and reduce the frequency of
visits to emergency rooms.
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